CN116462765A - 抗cd3和抗cd20双特异性抗体及其用途 - Google Patents

抗cd3和抗cd20双特异性抗体及其用途 Download PDF

Info

Publication number
CN116462765A
CN116462765A CN202310071807.3A CN202310071807A CN116462765A CN 116462765 A CN116462765 A CN 116462765A CN 202310071807 A CN202310071807 A CN 202310071807A CN 116462765 A CN116462765 A CN 116462765A
Authority
CN
China
Prior art keywords
formula
amino acid
seq
acid sequence
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310071807.3A
Other languages
English (en)
Chinese (zh)
Inventor
冯辉
周岳华
刘丹丹
刘洪川
李瑞胜
刘辉
何志娟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Junshi Biosciences Co Ltd
Original Assignee
Shanghai Junshi Biosciences Co Ltd
Suzhou Junmeng Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Junshi Biosciences Co Ltd, Suzhou Junmeng Biosciences Co Ltd filed Critical Shanghai Junshi Biosciences Co Ltd
Publication of CN116462765A publication Critical patent/CN116462765A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202310071807.3A 2022-01-20 2023-01-17 抗cd3和抗cd20双特异性抗体及其用途 Pending CN116462765A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022100685060 2022-01-20
CN202210068506 2022-01-20

Publications (1)

Publication Number Publication Date
CN116462765A true CN116462765A (zh) 2023-07-21

Family

ID=87183066

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310071807.3A Pending CN116462765A (zh) 2022-01-20 2023-01-17 抗cd3和抗cd20双特异性抗体及其用途

Country Status (8)

Country Link
US (1) US20250154275A1 (cg-RX-API-DMAC7.html)
EP (1) EP4467571A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025508317A (cg-RX-API-DMAC7.html)
KR (1) KR20240137640A (cg-RX-API-DMAC7.html)
CN (1) CN116462765A (cg-RX-API-DMAC7.html)
AU (1) AU2023209012A1 (cg-RX-API-DMAC7.html)
CA (1) CA3249231A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023138551A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025131075A1 (zh) * 2023-12-21 2025-06-26 上海君实生物医药科技股份有限公司 抗cd3和抗cd3多特异性抗体及用途
WO2026130456A1 (zh) * 2024-12-19 2026-06-25 上海橙帆医药有限公司 具有t细胞激活功能的抗体

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791075A1 (ru) * 2015-05-13 2017-11-30 Ридженерон Фармасьютикалз, Инк. Способы лечения опухолей с применением биспецифического антитела cd3×cd20
CN107660214A (zh) * 2015-01-08 2018-02-02 根马布股份公司 针对cd3和cd20的双特异性抗体
US20180194841A1 (en) * 2014-11-17 2018-07-12 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
CN110088135A (zh) * 2016-12-20 2019-08-02 豪夫迈·罗氏有限公司 抗cd20/抗cd3双特异性抗体和4-1bb(cd137)激动剂的组合疗法
CN110551221A (zh) * 2019-07-02 2019-12-10 广州爱思迈生物医药科技有限公司 一种双特异性抗体及其制备方法与应用
CN110603266A (zh) * 2016-06-02 2019-12-20 豪夫迈·罗氏有限公司 用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
CN111138545A (zh) * 2018-11-01 2020-05-12 安源医药科技（上海）有限公司 针对cd20和cd3的双特异性抗体及其用途
WO2020114479A1 (zh) * 2018-12-07 2020-06-11 江苏恒瑞医药股份有限公司 多特异性蛋白分子
TW202030206A (zh) * 2019-01-28 2020-08-16 大陸商上海藥明生物技術有限公司 新型雙特異性cd3/cd20多肽複合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2017210485A1 (en) * 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma
CN108059680B (zh) * 2017-12-26 2020-07-24 北京东方百泰生物科技有限公司 一种针对cd20和cd3的双特异性抗体
EP3847196A4 (en) * 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
TWI821474B (zh) * 2018-12-07 2023-11-11 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｄ３抗體及其藥物用途
CN115894701A (zh) * 2021-09-30 2023-04-04 上海君实生物医药科技股份有限公司 结合cd3的抗体及其用途

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180194841A1 (en) * 2014-11-17 2018-07-12 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
CN107660214A (zh) * 2015-01-08 2018-02-02 根马布股份公司 针对cd3和cd20的双特异性抗体
EA201791075A1 (ru) * 2015-05-13 2017-11-30 Ридженерон Фармасьютикалз, Инк. Способы лечения опухолей с применением биспецифического антитела cd3×cd20
CN110603266A (zh) * 2016-06-02 2019-12-20 豪夫迈·罗氏有限公司 用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
CN110088135A (zh) * 2016-12-20 2019-08-02 豪夫迈·罗氏有限公司 抗cd20/抗cd3双特异性抗体和4-1bb(cd137)激动剂的组合疗法
CN111138545A (zh) * 2018-11-01 2020-05-12 安源医药科技（上海）有限公司 针对cd20和cd3的双特异性抗体及其用途
WO2020114479A1 (zh) * 2018-12-07 2020-06-11 江苏恒瑞医药股份有限公司 多特异性蛋白分子
TW202030206A (zh) * 2019-01-28 2020-08-16 大陸商上海藥明生物技術有限公司 新型雙特異性cd3/cd20多肽複合物
CN110551221A (zh) * 2019-07-02 2019-12-10 广州爱思迈生物医药科技有限公司 一种双特异性抗体及其制备方法与应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025131075A1 (zh) * 2023-12-21 2025-06-26 上海君实生物医药科技股份有限公司 抗cd3和抗cd3多特异性抗体及用途
WO2026130456A1 (zh) * 2024-12-19 2026-06-25 上海橙帆医药有限公司 具有t细胞激活功能的抗体

Also Published As

Publication number Publication date
KR20240137640A (ko) 2024-09-20
WO2023138551A9 (zh) 2025-01-09
EP4467571A4 (en) 2026-02-25
AU2023209012A1 (en) 2024-09-05
CA3249231A1 (en) 2025-06-17
JP2025508317A (ja) 2025-03-26
US20250154275A1 (en) 2025-05-15
EP4467571A1 (en) 2024-11-27
WO2023138551A1 (zh) 2023-07-27

Similar Documents

Publication Publication Date Title
US20250154275A1 (en) Anti-cd3 and anti-cd20 bispecific antibody and use thereof
WO2023051727A1 (zh) 结合cd3的抗体及其用途
US20220363754A1 (en) Anti-tigit antibodies and application thereof
US20250346673A1 (en) Anti-bdca2 antibody and use thereof
US20240309087A1 (en) Anti-cd112r antibody and use thereof
CN116199778B (zh) 抗4-1bb抗体及其用途
WO2022017428A1 (zh) 抗ctla-4抗体及其用途
JP2025537484A (ja) Ｉｌ－１８受容体に対するヘテロマーアゴニスト抗体
CN121057752A (zh) 铰链经修饰的双特异性抗体
AU2021307516B2 (en) Anti-CLDN-18.2 antibody and use thereof
JP2025538606A (ja) 抗ｃｃｒ８抗体及びその使用
WO2023025303A1 (zh) 抗cldn-18.2抗体药物偶联物及其用途
WO2022063314A1 (zh) 靶向PD-1或PD-L1和TGF-β的双功能蛋白及其医药用途
HK40089487A (en) Anti-cd3 and anti-cd20 bispecific antibodies and uses thereof
US20240117043A1 (en) Bispecific antibody targeting cd112r and tigit and use thereof
WO2022037582A1 (zh) 抗cd3和抗cldn-18.2双特异性抗体及其用途
WO2025131077A1 (zh) 抗cd3多特异性抗体及用途
HK40089438B (en) Anti-cldn-18.2 antibody and use thereof
HK40089438A (zh) 抗cldn-18.2抗体及其用途
JP2023543826A (ja) 抗ｃｄ３抗体およびその使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40089487

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20241209

Address after: 201210 13th floor, building 2, No. 36 and 58, Haiqu Road, pilot Free Trade Zone, Pudong New Area, Shanghai

Applicant after: SHANGHAI JUNSHI BIOSCIENCES Co.,Ltd.

Country or region after: China

Address before: 201210 13th floor, building 2, No. 36 and 58, Haiqu Road, pilot Free Trade Zone, Pudong New Area, Shanghai

Applicant before: SHANGHAI JUNSHI BIOSCIENCES Co.,Ltd.

Country or region before: China

Applicant before: SUZHOU JUNMENG BIOSCIENCES Co.,Ltd.

TA01 Transfer of patent application right